These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35398589)

  • 1. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats.
    Brent MB; Brüel A; Thomsen JS
    Bone; 2022 Jul; 160():116417. PubMed ID: 35398589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.
    Brent MB; Thomsen JS; Brüel A
    Front Endocrinol (Lausanne); 2020; 11():588773. PubMed ID: 33162940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTH (1-34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats.
    Brent MB; Brüel A; Thomsen JS
    Bone; 2018 May; 110():244-253. PubMed ID: 29475111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
    Vegger JB; Nielsen ES; Brüel A; Thomsen JS
    Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.
    Sørensen TG; Brent MB; Thomsen JS; Brüel A
    Bone; 2020 Feb; 131():115183. PubMed ID: 31794846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice.
    Brent MB; Stoltenborg FE; Brüel A; Thomsen JS
    Front Endocrinol (Lausanne); 2021; 12():628994. PubMed ID: 33953694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats.
    Grubbe MC; Thomsen JS; Nyengaard JR; Duruox M; Brüel A
    J Musculoskelet Neuronal Interact; 2014 Dec; 14(4):473-83. PubMed ID: 25524973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
    Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
    Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin A.
    Brent MB; Lodberg A; Thomsen JS; Brüel A
    MethodsX; 2020; 7():101079. PubMed ID: 33083241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice.
    Brent MB; Lodberg A; Bromer FD; van der Eerden BCJ; Eijken M; Brüel A; Thomsen JS
    Bone; 2021 Jan; 142():115692. PubMed ID: 33069923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
    Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.
    Brent MB; Thomsen JS; Brüel A
    Sci Rep; 2021 Jun; 11(1):12258. PubMed ID: 34112892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading.
    Teguh DA; Nustad JL; Craven AE; Brooks DJ; Arlt H; Hu D; Baron R; Lanske B; Bouxsein ML
    Bone; 2021 Mar; 144():115801. PubMed ID: 33338664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.
    Brüel A; Vegger JB; Raffalt AC; Andersen JE; Thomsen JS
    Bone; 2013 Mar; 53(1):51-8. PubMed ID: 23246791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertical Trabeculae are Thinned More Than Horizontal Trabeculae in Skeletal-Unloaded Rats.
    Vegger JB; Brüel A; Thomsen JS
    Calcif Tissue Int; 2015 Nov; 97(5):516-26. PubMed ID: 26163234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J; Cai XH; Qin XX; Liu YX
    Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.
    Costa S; Fairfield H; Reagan MR
    Bone; 2019 Jun; 123():211-223. PubMed ID: 30954729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.
    Vegger JB; Brüel A; Thomsen JS
    J Musculoskelet Neuronal Interact; 2017 Sep; 17(3):162-175. PubMed ID: 28860418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.